Format

Send to

Choose Destination
Hum Vaccin. 2010 Nov;6(11):881-7. Epub 2010 Nov 1.

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.

Author information

1
Novartis Vaccines and Diagnostics, Cambridge, MA, USA. christopher.gill@novartis.com

Abstract

The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00856297.

PMID:
21339701
PMCID:
PMC3060384
DOI:
10.4161/hv.6.11.12849
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center